

# Lactoferrin reduces febrile neutropenia in children receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled trial

## Authors

---

Nunzia Decembrino,<sup>1</sup> Daniele Zama,<sup>2,3</sup> Edoardo Muratore,<sup>4</sup> Paola Muggeo,<sup>5</sup> Katia Perruccio,<sup>6</sup> Virginia Vitale,<sup>7</sup> Antonella Colombini,<sup>8</sup> Valentina Kiren,<sup>9</sup> Rosamaria Mura,<sup>10</sup> Raffaella De Santis,<sup>11</sup> Santina Recupero,<sup>12</sup> Riccardo Masetti,<sup>4</sup> Gloria Tridello,<sup>7</sup> Catherine Klersy,<sup>13</sup> Luigia Scudeller,<sup>13</sup> Marco Zecca<sup>12#</sup> and Simone Cesaro<sup>7#</sup>

<sup>1</sup>Neonatal Intensive Care Unit Unit-AOU Policlinico “Rodolico-San Marco”, University of Catania, Catania; <sup>2</sup>Pediatric Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna; <sup>3</sup>Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna; <sup>4</sup>Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna; <sup>5</sup>Pediatric Hematology and Oncology, University Hospital of Policlinico, Bari; <sup>6</sup>Pediatric Hematology and Oncology Department, “Santa Maria della Misericordia” Hospital, Perugia; <sup>7</sup>Pediatric Hematology and Oncology, Department of the Mother and the Child, Azienda Ospedaliera

Universitaria Integrata Verona, Verona; <sup>8</sup>Pediatric Hematology/Oncology Fondazione Monza e Brianza per il Bambino e la Mamma, Monza; <sup>9</sup>Pediatric Hematology/Oncology IRCCS Burlo Garofalo, Trieste; <sup>10</sup>Pediatric Hematology and Oncology Unit, ARNAS G. Brotzu, Cagliari; <sup>11</sup>Pediatric Hematology/Oncology, IRCCS Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia; <sup>12</sup>Pediatric Hematology/Oncology IRCCS San Matteo Hospital Foundation, Pavia and <sup>13</sup>Clinical Epidemiology and Biometry, IRCCS San Matteo Hospital Foundation, University of Pavia, Pavia, Italy

*#MZ and SC contributed equally as senior authors.*

Correspondence:

E: MURATORE - edoardo.muratore@studio.unibo.it

D. ZAMA - daniele.zama2@unibo.it

<https://doi.org/10.3324/haematol.2025.300007>

1 **Supplementary Table S1** Blood cultures result in the two study arms.

2

	Treatment group	
	Placebo	bLf arm
<b>Pathogen</b>		
Pseudomonas aeruginosa	3	3
Escherichia Coli	1	2
Staphylococcus haemolyticus	3	0
Staphylococcus epidermidis	0	3
Staphylococcus hominis	0	1
Streptococcus mitis	0	1
Streptococcus oralis	1	0
Streptococcus mitis/oralis	1	0
Enterococcus gallinarum	0	1
Enterococcus faecium	0	1
Brevibacterium	1	0
Klebsiella Pneumoniae	1	0
Klebsiella varicola	0	1
Klebsiella Pneumoniae + Staphylococcus epidermidis	1	0
Pseudomonas aeruginosa + Staphylococcus haemolyticus	1	0
<b>Total</b>	<b>13</b>	<b>13</b>

3

4

5


6

7 Supplementary Figure S1. Screened patients, allocation and drop-out

8 Supplementary Figure S2. CI of FN < 0.5 G/L by study arms


9

10



Supplementary Figure S1

Cumulative incidence of FN (< 0.5 G/L)



Patients at risk

<i>Placebo</i>	77	72	61	49	48	43	43	39	31	24	19	16	11	8
<i>bLF</i>	79	75	70	65	60	57	55	53	44	36	32	27	24	18